Pharmaron Beijing Co., Ltd.
300759
Rangering i aksjer
#2354
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a... Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Aksjekurs
$5.58
Markedsverdi
$8.24B
Endring (1 dag)
-3.77%
Endring (1 år)
28.36%
Land
CN
Handel Pharmaron Beijing Co., Ltd. (300759)
Kategori
Healthcare
Inntekter for Pharmaron Beijing Co., Ltd. (300759)
Inntekter i Jun 2026 TTM: $2.28B
Ifølge de nyeste økonomiske rapportene til Pharmaron Beijing Co., Ltd. er selskapets nåværende inntekter (TTM) $2.28B. I 2024 hadde selskapet inntekter på $1.68B en økning sammenlignet med inntektene i 2023, som var $1.63B. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Pharmaron Beijing Co., Ltd. fra 2014 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $2.28B | 12.93% |
| 2025 | $2.01B | 19.79% |
| 2024 | $1.68B | 3.18% |
| 2023 | $1.63B | 9.52% |
| 2022 | $1.49B | 27.08% |
| 2021 | $1.17B | 49.03% |
| 2020 | $785.83M | 45.64% |
| 2019 | $539.57M | 27.62% |
| 2018 | $422.78M | 19.90% |
| 2017 | $352.61M | 49.80% |
| 2016 | $235.38M | 35.50% |
| 2015 | $173.71M | 36.12% |
| 2014 | $127.61M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $12.62B | 454.89% |
US
|
|
| $2.23B | -2.07% |
US
|
|
| $15.74B | 592.03% |
AU
|
|
| $10.11B | 344.41% |
BE
|
|
| $6.02B | 164.66% |
NL
|
